OKYO Pharma Limited
NASDAQ:OKYOBiotechnology
+$0.01 today
- Market cap
- $57.73M
- Beta
- 0.02
- P/E (TTM)
- -12.8
- EPS (TTM)
- -$0.12
Volume 0.24M
Average 0.07M
OKYO Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
OKYO Pharma LimitedNASDAQ: OKYO
Operating Expenses · Q2 FY2026 · quarter ended Sep 2025
Operating expenses grows 252169.1% year over year
Q2 FY2026 operating expenses of $2.79M rose 252169.1% year over year. Over 3 fiscal years it compounded at +4.9% a year.
Context
- Operating expenses increased in 2 of the last 3 fiscal years.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 7.19M USD
- Year-over-year change
- -54.2%
- 4-year CAGR
- +20.9%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-03-31 | 7.19M | -54.2% |
| FY2024 | 2024-03-31 | 15.69M | +147.6% |
| FY2023 | 2023-03-31 | 6.34M | +1.9% |
| FY2022 | 2022-03-31 | 6.22M | +84.7% |
| FY2021 | 2021-03-31 | 3.37M | — |
Operating Expenses vs competitors
How OKYO compares with its peers on the latest reported figures
- OKYO's FY2025 operating expenses of $7.19M is the lowest of the 10 companies compared; the peer median is $35.95M.
- Its year-over-year change of -54.2% is the lowest of 10, against a peer median of -10.6%.
- Over three fiscal years its annual growth of +4.9% compares with a peer median of +5.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $173.51M | -10.6% | -12.1% | 110.5% | |
| LTM Mar 2026 | $144.89M | -39.4% | -12.4% | — | |
WHWKWhitehawk Therapeutics Inc | LTM Mar 2026 | $122.7M | +143.6% | +40.1% | — |
| LTM Mar 2026 | $118.5M | -49.4% | +2.7% | — | |
| LTM Mar 2026 | $35.95M | +65.2% | +48.4% | — | |
| LTM Mar 2026 | $29.92M | +225.6% | +73.5% | 376.8% | |
| FY2025 | $21.05M | +33.3% | +5.5% | — | |
| LTM Mar 2026 | $20.79M | -21.5% | +53.5% | 112.6% | |
| LTM Mar 2026 | $20.57M | -27.1% | -21.9% | 15353.0% | |
| FY2025 | $7.19M | -54.2% | +4.9% | — | |
| Peer median (excluding OKYO) | $35.95M | -10.6% | +5.5% | 244.7% | |
Competitors are the stored peer set for OKYO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Mar 2021 | FY2022 Mar 2022 | FY2023 Mar 2023 | FY2024 Mar 2024 | FY2025 Mar 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 13.09K | 2.42K | 3.8K | 3.87K | 2.56K |
| Gross Profit | (13.09K) | (2.42K) | (3.8K) | (3.87K) | (2.56K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 348.35K | 1.61M | 6.34M | 8.24M | 2.25M |
| Selling, General & Admin | 2.97M | 4.93M | 6.75M | 7.45M | 4.93M |
| Operating Expenses | 3.37M | 6.22M | 6.34M | 15.69M | 7.19M |
| Depreciation & Amortization | 13.11K | 2.33K | 3.8K | 3.87K | 2.56K |
| EBITDA | (3.35M) | (6.22M) | (13.18M) | (15.75M) | (7.08M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (4.13M) | (6.23M) | (13.09M) | (15.69M) | (7.19M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 0 | 0 | 5.47K |
| Interest Expense | 1.12K | 0 | 96.69K | 1.05M | 883.65K |
| Other Income / Expenses | 754.85K | 13.58K | (196.62K) | (1.11M) | (781.2K) |
| Income Before Tax | (3.38M) | (6.22M) | (13.28M) | (16.8M) | (7.97M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | (24.99K) | (787K) | (12.2K) | 22.42K | (3.26M) |
| Net Income | (3.35M) | (5.43M) | (13.27M) | (16.83M) | (4.71M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.32) | (0.36) | (0.60) | (0.00) | (0.12) |
| EPS (Diluted) | (0.32) | (0.36) | (0.60) | (0.00) | (0.12) |
| Weighted Avg Shares | 10.35M | 15.06M | 22.26M | 29.34M | 39.49M |
| Weighted Avg Shares (Diluted) | 10.35M | 15.06M | 22.26M | 29.34M | 39.49M |
OKYO Pharma Limited
NASDAQ:OKYO
Intrinsic Alpha fair value
Locked
Current Price
$1.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.